Psychiatry
1 drug is in development for Cognitive Impairment.
- Companies
- 1
- Clinical trials
- 20
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Cognitive Impairment pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ALTO-101 | Alto Neuroscience, Inc. (ANRO) |
About this indication
Cognitive Impairment context
Psychiatry·MeSH: Cognitive Dysfunction (D060825)
Also known as: Cognitive Disorders, Cognitive Dysfunctions, Disorder, Cognitive, Dysfunction, Cognitive, Impairments, Cognitive
Narrower concepts tracked separately: Mild Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment (MCI)
Frequently asked questions
How many drugs are in development for Cognitive Impairment?
BioSniper tracks 1 drug in development for Cognitive Impairment across 1 company.
How many clinical trials target Cognitive Impairment?
There are 20 clinical trials targeting Cognitive Impairment tracked by BioSniper.